Cellular Immunology, Journal Year: 2024, Volume and Issue: 407, P. 104898 - 104898
Published: Nov. 28, 2024
Language: Английский
Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15
Published: June 28, 2024
Chimeric antigen receptor T (CAR-T) cell therapy has revolutionized the treatment of hematological malignancies, demonstrably improving patient outcomes and prognosis. However, its application introduced new challenges, such as safety concerns, off-target toxicities, significant costs. Natural killer (NK) cells are crucial components innate immune system, capable eliminating tumor without prior exposure to specific antigens or pre-activation. This inherent advantage complements limitations cells, making CAR-NK a promising avenue for immunotherapy. In recent years, preclinical clinical studies have yielded preliminary evidence supporting efficacy in paving way future advancements review aims succinctly discuss characteristics, therapeutic progress, potential challenges associated with therapy.
Language: Английский
Citations
6
Best Practice & Research Clinical Haematology, Journal Year: 2025, Volume and Issue: unknown, P. 101631 - 101631
Published: May 1, 2025
Language: Английский
Citations
0
Journal of Translational Medicine, Journal Year: 2024, Volume and Issue: 22(1)
Published: Aug. 5, 2024
Asthma poses a major public health burden. While existing asthma drugs manage symptoms for many, some patients remain resistant. The lack of cure, especially severe asthma, compels exploration novel therapies. Cancer immunotherapy successes with CAR-T cells suggest its potential treatment. Researchers are exploring various approaches allergic diseases including membrane-bound IgE, IL-5, PD-L2, and CTLA-4 Dectin-1 fungal asthma. NK offer several advantages over T CAR-based immunotherapy. They key benefits: (1) HLA compatibility, meaning they can be used in wider range without the need matching tissue types. (2) Minimal side effects (CRS GVHD) due to their limited persistence cytokine profile. (3) Scalability "off-the-shelf" production from sources. Several strategies have been introduced that highlight superiority challenges CAR-NK cell therapy treatment IL-10, IFN-γ, ADCC, perforin-granzyme, FASL, KIR, NCRs (NKP46), DAP, DNAM-1, TGF-β, TNF-α, CCL, NKG2A, TF, EGFR. Furthermore, we advocate incorporating AI CAR design optimization CRISPR-Cas9 gene editing technology precise manipulation generate highly effective constructs. This review will delve into evolution designs, explore pre-clinical clinical studies therapies analyze optimize function, conduct comparative analysis respective challenges, finally present established designs promising
Language: Английский
Citations
2
Ageing & Longevity, Journal Year: 2024, Volume and Issue: 4 2024, P. 157 - 173
Published: Nov. 11, 2024
Chimeric Antigen Receptor (CAR) Natural Killer (NK) cells represent a promising advancement in cancer immunotherapy, particularly for targeting circulating tumor (CTCs) and preventing metastasis. This review examines the latest developments CAR NK cell therapy, including diverse sources, genetic engineering techniques, dual mechanisms of action. Targeting CTCs with shows significant potential aggressive cancers like triple-negative breast (TNBC) pancreatic cancer. The impact aging on function, especially regarding cytotoxicity, cytokine secretion, persistence, poses challenges elderly patients, but strategies such as interleukin-15 metabolic interventions offer solutions. also addresses current limitations, poor persistence immunosuppressive microenvironments low solid infiltration, while proposing combination therapies to enhance effectiveness. Although still earlier clinical stages compared T cells, cells’ safety profile MHC-independent recognition make them versatile therapeutic option. Future directions include optimizing improving developing age-adapted patients. _________________________________________________________________________________________ Keywords: Circulating (CTCs), Cell Therapy, Aging
Language: Английский
Citations
0
Cellular Immunology, Journal Year: 2024, Volume and Issue: 407, P. 104898 - 104898
Published: Nov. 28, 2024
Language: Английский
Citations
0